º» »ó´ãÀº °ø°³µÇ¹Ç·Î ºñ°ø°³»ó´ãÀ» ¿øÇϽøé [ÀüÈ­»ó´ã¿¹¾à¶õ]À¸·Î ¹®ÀÇÇϽñ⠹ٶø´Ï´Ù.
[º» ÀÇ·á »ó´ãÀº Áø·á¸¦ ´ë½Å ÇÒ ¼ö ¾ø½À´Ï´Ù.]


LTK ½Ã¼ú°ü·Ã ¹®ÀÇ ÇÕ´Ï´Ù.
±Û   ¾´   ÀÌ ÃÖÈĶô
º»         ¹® ¾È³çÇϼ¼¿ä.

¾Æ¹ö´Ô²²¼­ ±ÝÁÖ¿¡ ¼ö¼ú¿¹¾àÀÌ µÇ¾î ÀÖ½À´Ï´Ù.

»çÀü¿¡ ¸¹Àº º» ½Ã¼ú¿¡ ¸¹Àº Áö½ÄÀÌ ¾ø´Â °ü°è·Î ±× Ÿ´ç¼ºÀ» ¼±»ý´Ô²² ÀüÀûÀ¸·Î ÀÇÁ¸ÇØ¾ß ÇÏ´Â ÀÔÀåÀÔ´Ï´Ù.
¸¹Àº Á¡ÀÌ ±Ã±ÝÇÏ¿©, ÇØ¿Ü ¹®ÇåÀ» Á¶»çÇØ º¸´ø Áß FDA¿¡¼­ ½ÂÀÎÇÒ ´ç½Ã ÀÓ»ó°á°ú¿Í 2004³â º¸µµÀڷḦ º¸´Ï,
Á¡Â÷ ´«ÀÌ ¿ø·¡ »óÅ·Πµ¹¾Æ°¥ È®À²ÀÌ CK, ASA80º¸´Ù ³ôÀº °ÍÀ¸·Î ³ª¿ÍÀÖ´õ±º¿ä.

¾î¶² ¹æ¹ýÀ¸·Î ¼ö¼úÇϽñ⿡ ¼±»ý´Ô²²¼± "°ÅÀÇ ¹®Á¦°¡ ¹ß»ýµÇÁö ¾Ê´Â´Ù"¶ó°í ¸»¾¸Çϼ̴ÂÁö ±Ã±ÝÇÕ´Ï´Ù. ¶ÇÇÑ ´ëºÎºÐ 2³âÁ¤µµ¿¡ ½Ã·ÂÀÌ ¾ÈÁ¤È­ µÈ´Ù°í ÇÏ´øµ¥, ±× »çÀÌ¿¡ ½Ã·ÂÀÌ ¸¹ÀÌ ¿øº¹µÇ¸é ¾î¶² Á¶Ä¡¸¦ ÃëÇØ Áֽô°¡µµ ±Ã±ÝÇÕ´Ï´Ù.

Á¦ ¾Æ¹ö´ÔÀÇ ¼ÒÁßÇÑ ´«À» Á¦°¡ ³ª¼­¼­ ¼ö¼úÇÏÀÚ°í ÇÏ´Â ÀÔÀåÀÌ¶ó ¼±»ý´Ô²² ¾ð¨Àº ±ÛÀ» ¿Ã¸°°Ç ¾Æ´Ñ°¡ Á˼۽º·´½À´Ï´Ù.

¹Ù»Ú½Ã´õ¶óµµ Àß ¸ô¶ó ¾ÈŸ±î¿î ¸¶À½¿¡ ±ÛÀ» ¿Ã¸®¿À´Ï ȸ½Å ºÎŹµå¸³´Ï´Ù.

- ÷ºÎÀÚ·á -

The data analysis was based on the refractive data at all follow-up examination time points (1 month, 3, 6, 12, 18 and 24 months). At 12 months, this analysis showed that 407/409 (85.0%) eyes were corrected to 20/40 or better and 179/479 (37.4%) were corrected to 20/20 or better visual acuity without spectacles or contact lenses. 5e. The study showed that all adverse events occurred at low rates (<1%).

Sunrise Corporation used a non-contact
Holmium laser to apply a ring of spots to
the cornea. LTK fell from favour as many
patients had significant regression by 12
months.

Laser thermal keratoplasty (LTK).
Sunrise¡¯s Hyperion laser system was
approved by the FDA for the
temporary correction of hyperopia.

Long term risks of LTK for hyperopia have not been determined. The safety and effectiveness of re-treatment procedures with the HYPERION¢â LTK System or other refractive surgical devices have not been established. Limited data suggests that the reduction in refractive error following re-treatment may diminish over time.

¸ñ·ÏÀ¸·Î